Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
Open Access
- 1 August 2003
- journal article
- case report
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 9 (8) , 505-511
- https://doi.org/10.1016/s1083-8791(03)00216-7
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Treating human autoimmune disease by depleting B cellsAnnals of the Rheumatic Diseases, 2002
- Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneBlood, 2002
- Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivityNature Immunology, 2001
- Chronic graft-versus-host disease: clinical manifestation and therapyBone Marrow Transplantation, 2001
- Advances in transplantation toleranceThe Lancet, 2001
- Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2001
- Role of perforin in controlling B-cell hyperactivity and humoral autoimmunityJournal of Clinical Investigation, 2000
- Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processesJournal of Clinical Investigation, 2000
- Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host DiseaseAnnals of Internal Medicine, 2000
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998